학술논문

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
Document Type
Article
Source
In The Lancet Oncology December 2024 25(12):1576-1588
Subject
Primary Research
Articles
Language
ISSN
1470-2045
Abstract
Funding US National Cancer Institute and AstraZeneca.